Prudential Bancorp, Inc. (PBIP) Touches $17.77 Formed H&S; Endo Health Solutions Has 1.13 Sentiment

Prudential Bancorp, Inc. (NASDAQ:PBIP) Logo

Prudential Bancorp, Inc. (PBIP) formed inverse H&S with $18.30 target or 3.00% above today’s $17.77 share price. Prudential Bancorp, Inc. (PBIP) has $159.90 million valuation. The stock increased 0.45% or $0.08 during the last trading session, reaching $17.77. About 5,471 shares traded. Prudential Bancorp, Inc. (NASDAQ:PBIP) has risen 0.53% since May 17, 2017 and is uptrending. It has underperformed by 11.02% the S&P500.

Endo Health Solutions Inc (ENDP) investors sentiment increased to 1.13 in 2017 Q4. It’s up 0.01, from 1.12 in 2017Q3. The ratio has increased, as 111 funds increased and opened new holdings, while 98 cut down and sold their holdings in Endo Health Solutions Inc. The funds in our database now hold: 203.77 million shares, up from 202.81 million shares in 2017Q3. Also, the number of funds holding Endo Health Solutions Inc in top ten holdings was flat from 2 to 2 for the same number . Sold All: 37 Reduced: 61 Increased: 72 New Position: 39.

Analysts await Endo International plc (NASDAQ:ENDP) to report earnings on August, 14. They expect $0.55 EPS, down 40.86% or $0.38 from last year’s $0.93 per share. ENDP’s profit will be $123.11M for 2.84 P/E if the $0.55 EPS becomes a reality. After $0.67 actual EPS reported by Endo International plc for the previous quarter, Wall Street now forecasts -17.91% negative EPS growth.

Broadfin Capital Llc holds 3.09% of its portfolio in Endo International plc for 2.44 million shares. Tpg Group Holdings (Sbs) Advisors Inc. owns 22.15 million shares or 2.63% of their US portfolio. Moreover, Kamunting Street Capital Management L.P. has 1.44% invested in the company for 261,740 shares. The New York-based Deltec Asset Management Llc has invested 1.22% in the stock. Bogle Investment Management L P De, a Massachusetts-based fund reported 1.97 million shares.

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. The company has market cap of $1.40 billion. The Company’s U.S. It currently has negative earnings. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets.

More important recent Endo International plc (NASDAQ:ENDP) news were published by: Seekingalpha.com which released: “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018, also Seekingalpha.com published article titled: “Endo Pharmaceuticals Earnings Preview”, Streetinsider.com published: “Paulson’s 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more…)” on May 15, 2018. More interesting news about Endo International plc (NASDAQ:ENDP) was released by: Streetinsider.com and their article: “Glenview Capital Enters AmerisourceBergen (ABC), Express Scripts (ESRX), T-Mobile (TMUS) (more…) -13F” with publication date: May 15, 2018.

Ratings analysis reveals 50% of Endo Intl’s analysts are positive. Out of 4 Wall Street analysts rating Endo Intl, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $21.0 while the high is $25.0. The stock’s average target of $23 is 268.00% above today’s ($6.25) share price. ENDP was included in 4 notes of analysts from November 9, 2016. JP Morgan downgraded the stock to “Neutral” rating in Friday, January 20 report. The firm earned “Neutral” rating on Thursday, January 5 by Citigroup. The company was maintained on Wednesday, November 9 by RBC Capital Markets. Mizuho maintained the shares of ENDP in report on Friday, November 11 with “Buy” rating.

Endo International plc (NASDAQ:ENDP) Ratings Chart